Gilead to sell notes in four parts to fund Kite Pharma acquisition

By Devika Patel

Knoxville, Tenn., Sept. 14 – Gilead Sciences Inc. intends to offer notes in four tranches, according to a 424B5 filing with the Securities and Exchange Commission.

The notes will be sold in three floating-rate tranches and a fixed-rate senior tranche.

The fixed-rate portions will have make-whole calls and then par calls. The floaters will be non-callable.

BofA Merrill Lynch and Wells Fargo Securities LLC are the joint bookrunners.

Proceeds will be used as part of the financing for the company’s planned acquisition of Kite Pharma, Inc.

The biopharmaceutical company is based in Foster City, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.